Мирон Кордуба і Микола Андрусяк: до історії взаємин

У статті проаналізовано взаємини українських істориків М. Кордуби та М. Андрусяка, зокрема висвітлено їхні особисті та творчі контакти. Також подано погляди учених на проблеми розвитку української науки, діяльність НТШ та національне книговидання тощо. Охарактеризовано взаємне листування вчених. У додатку до статті вміщено епістолярій М. Кордуби та М. Андрусяка.В статье проанализированы взаимоотношения украинских историков М. Кордубы и Н. Андрусяка, представлены их взгляды на развитие украинской науки, национальное книгоиздание, деятельность Научного общества имени Шевченко во Львове. Охарактеризовано переписку ученых. В приложении к статье помещены письма М. Кордубы и Н. Андрусяка.The article analyzes relationships of the Ukrainian historians M.Korduba and M.Andrusyak, in particular it highlights their personal and professional contacts. Also, the views of scientists on the problems of the Ukrainian science development, activities of Shevchenko Scientific Society and the national book publishing, etc. are given. The correspondence of two scientists is characterized. Correspondence of M. Korduba and M. Andrusiak is given in the appendix to the article

Evaluation of an individualized dosing regimen of busulfan in children undergoing allogeneic haematopoietic stem cell transplantation

OBJECTIVE To assess target attainment of busulfan exposure using a new model-based dosing regimen and therapeutic drug monitoring (TDM). Busulfan is an alkylating drug used in conditioning regimens for allogeneic haematopoietic cell transplantation (allo-HCT). Its narrow therapeutic range in combination with large interindividual variability in exposure, even after intravenous administration, necessitates dose individualization. DESIGN Prospective cohort study. METHODS All children who underwent allo-HCT in 2011 or 2012 receiving busulfan-based conditioning were included. Intravenous busulfan was administered once daily on four consecutive days and drug levels were measured on days 1 and k. For each patient a 'hypothetical' exposure (cAUC) without TDM was determined by extrapolating the AUC of day 1. The 'true' cAUC was then estimated based on pharmacokinetic data obtained on days 1-4 including TDM-based dose adjustment. Means and ranges were compared between cAUCs determined with and without TDM-based dose corrections. Also target attainment rates (cAUC 80-100 mg-h/L] were compared between 'hypothetical' and 'true' exposure. RESULTS 50 patients were included. Without TDM mean cAUC was 85.3 mg-h/L versus 96.2 mg-h/L with TDM. The range in individual cAUCs was significantly larger without TDM than with TDM IP = 0.001 ). Without TDM 34% of patients reached target cAUC and with TDM this significantly increased to 70% of patients (P = 0.0011. CONCLUSION The weight-based dosing regimen overall led to a mean busulfan exposure within the target range, yet the interindividual variation was substantial. Therefore, TDM of intravenous busulfan remains recommended and is of utmost importance to reach optimal target exposure in order to optimize HCT outcomes

Элементы природы в крымско–татарском народном искусстве

В статье рассматривается система образования элементов орнамента. Типы орнаментального искусства и принципы группировки элементов изобразительной формы. Цветовое решение в орнаменте.В статі розглядається система освіти елементів орнамента. Типи орнаментального мистецтва і принципи згрупування елементів образотворчої форми. Кольорове рішення в орнаменті.The system of ornament's elements is representative in this article. Same types of art's ornament and some principles of grouping art's elements are here. Color's design in ornament

О противодействии недружественным слияниям и поглощениям в сельском хозяйстве

Целью данной работы является определение путей повышения эффективности противодействия рейдерству в аграрной сфере Украины

Catalan Abstracts

OBJECTIVE: This retrospective study addresses the cost-effectiveness of add-on therapy with lamotrigine in clinical practice. METHODS: Two years' observational data of 165 patients were used. Seizure frequency, adverse effects and direct medical costs were recorded for the year before and the year after the start of lamotrigine add-on therapy. Therapy effectiveness was measured by: (1) reduction in seizure frequency and (2) retention time. The incremental cost-effectiveness ratio expressed the direct medical cost per patient treated effectively with lamotrigine. RESULTS: The cost of medication was 492 (95% CI: 399-583) higher after the start of lamotrigine therapy. The extra cost of lamotrigine therapy (622) was partly offset by a reduction of the cost of co-medication (-130; 95% CI: -210 to -50). Overall, the total medical cost was 453 higher in the first year of lamotrigine therapy than in the year before the start of lamotrigine. Lamotrigine was effective in 47% of all the patients, making the resultant incremental cost-effectiveness ratio 954 per year. DISCUSSION: Add-on therapy of lamotrigine for patients with uncontrolled epilepsy offers improved health outcomes. Lamotrigine therapy is associated with increased cost (453) and an annual incremental cost-effectiveness ratio of 954. These data, together with utility data published in the literature, support the notion that lamotrigine should be considered as an add-on therapy in for patients with refractory epilepsy